GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » Cyclically Adjusted FCF per Share

Avadel Pharmaceuticals (STU:AWK) Cyclically Adjusted FCF per Share : €-0.80 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Avadel Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.298. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.80 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -13.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -14.90% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Avadel Pharmaceuticals was 37.30% per year. The lowest was -46.70% per year. And the median was -1.45% per year.

As of today (2024-06-01), Avadel Pharmaceuticals's current stock price is €14.60. Avadel Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-0.80. Avadel Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Avadel Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Avadel Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Avadel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.46 -0.45 -0.61 -0.68 -0.81

Avadel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.74 -0.70 -0.83 -0.81 -0.80

Competitive Comparison of Avadel Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Avadel Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Avadel Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.298/120.9901*120.9901
=-0.298

Current CPI (Mar. 2024) = 120.9901.

Avadel Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.109 100.773 -0.131
201409 0.056 100.474 0.067
201412 -0.137 99.576 -0.166
201503 0.540 99.975 0.654
201506 0.300 100.573 0.361
201509 0.399 100.274 0.481
201512 0.445 99.676 0.540
201603 0.434 99.676 0.527
201606 -0.102 101.072 -0.122
201609 -0.108 100.274 -0.130
201612 0.173 99.676 0.210
201703 0.545 100.374 0.657
201706 0.173 100.673 0.208
201709 -1.125 100.474 -1.355
201712 -0.310 100.075 -0.375
201803 -0.380 100.573 -0.457
201806 -0.931 101.072 -1.114
201809 -0.472 101.371 -0.563
201812 -0.582 100.773 -0.699
201903 -0.503 101.670 -0.599
201906 -0.034 102.168 -0.040
201909 -0.180 102.268 -0.213
201912 -0.198 102.068 -0.235
202003 -0.256 102.367 -0.303
202006 -0.099 101.769 -0.118
202009 -0.149 101.072 -0.178
202012 -0.257 101.072 -0.308
202103 -0.337 102.367 -0.398
202106 -0.144 103.364 -0.169
202109 -0.308 104.859 -0.355
202112 -0.340 106.653 -0.386
202203 -0.526 109.245 -0.583
202206 -0.226 112.779 -0.242
202209 -0.114 113.504 -0.122
202212 -0.233 115.436 -0.244
202303 -0.442 117.609 -0.455
202306 -0.383 119.662 -0.387
202309 -0.401 120.749 -0.402
202312 -0.286 120.749 -0.287
202403 -0.298 120.990 -0.298

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Avadel Pharmaceuticals  (STU:AWK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Avadel Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals (STU:AWK) Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.